HIV Prevention and Adherence Among Priority Drug Using Populations

优先吸毒人群的艾滋病毒预防和依从性

基本信息

批准号：
8628827
负责人：
MICHAEL COPENHAVER
金额：
$ 13.94万
依托单位：
UNIVERSITY OF CONNECTICUT STORRS
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-04-01 至 2018-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8628827
关键词：
AIDS prevention AIDS/HIV problem Acquired Immunodeficiency Syndrome Adherence Adopted Allied Health Sciences Anti-Retroviral Agents Applications Grants Area Awareness Behavior Behavior Therapy Centers for Disease Control and Prevention (U.S.)Clinical Clinical Sciences Collaborations Committee Members Communicable Diseases Connecticut Development Diffusion Drug Addiction Drug usage Drug user Epidemic Evaluation Evidence based intervention Funding Future Goals Grant HIV HIV Infections HIV risk Health Health Psychology Health behavior Human Independent Scientist Award Individual Infection Institutes Interdisciplinary Study International Intervention Life Literature Medicine Mentors Mentorship Monitor NCI Scholars Program National Institute of Drug Abuse Outcome Persons Pharmaceutical Preparations Physicians Population Postdoctoral Fellow Prevention approach Preventive Intervention Productivity Public Health Publications Qualifying Research Research Activity Research Personnel Resources Risk Behaviors Risk Reduction Science Scientist Substance abuse problem Testing Time Training Translational Research United States National Institutes of Health Universities Wood material Work career clinical care college cost effective design disorder prevention evidence base high risk improved intervention program next generation pandemic disease pre-doctoral programs public health relevance sex symposium treatment program uptake

项目摘要

DESCRIPTION (provided by applicant): In this revised K02 career grant application, the candidate is requesting 5 years of funding to support a range of activities that will collectively improve the development of HIV prevention and adherence intervention approaches targeting drug users nationally and internationally. Through the CDC's Diffusion of Effective Behavioral Interventions (DEBI) program, a number of evidence-based HIV prevention approaches are now widely available for use with people living with HIV/AIDS (PLWA). The substantial resources required for training, implementation, monitoring, and evaluation of current EBIs targeting HIV+ DUs, however, reduces the likelihood that these EBIs can be properly adopted and sustained in common clinical settings (e.g., drug treatment programs, HIV clinical care settings, correctional settings, etc.). Moreover, the uptake of EBIs applicable to HIV+ DUs has been quite limited and the number of new annual HIV infections - a significant portion of which are directly and indirectly attributable to HIV+ DUs - has remained ~56,300 in the U.S. Thus, HIV+ DUs remain an important priority population since only HIV+ persons can transmit new infections and because DUs continue to contribute greatly to the persistent HIV epidemic via drug- and sex-related HIV risk behaviors that are entirely preventable through properly tailored and strategically placed interventions that are efficacious, cost-effective, and sustainable in clinica settings. NIDA has recognized this translational gap and has provided funding for the candidate's research team to adapt and optimize EBI approaches for implementation among priority populations in drug treatment and correctional settings. The activities proposed in this revised K02 (Independent Scientist Award) provide the essential framework and release time for the candidate to contribute to the next generation of HIV prevention and adherence programs targeting this priority population with the ultimate goal of improving the HIV pandemic.

描述（由申请人提供）：在这份修订后的 K02 职业补助金申请中，候选人请求 5 年的资金来支持一系列活动，这些活动将共同改善针对国内和国际吸毒者的艾滋病毒预防和依从性干预方法的发展。通过 CDC 的有效行为干预扩散 (DEBI) 计划，许多基于证据的艾滋病毒预防方法现已广泛用于艾滋病毒/艾滋病患者 (PLWA)。然而，当前针对 HIV+ DU 的 EBI 的培训、实施、监测和评估所需的大量资源降低了这些 EBI 在常见临床环境（例如药物治疗计划、HIV 临床护理环境、矫正设置等）。此外，适用于 HIV+ DU 的 EBI 的采用相当有限，并且美国每年新增的 HIV 感染人数（其中很大一部分直接或间接归因于 HIV+ DU）仍约为 56,300 例。因此，HIV+ DU 仍然是重要的优先人群，因为只有艾滋病毒阳性者才能传播新的感染，并且吸毒者通过与毒品和性相关的艾滋病毒风险行为继续对艾滋病毒的持续流行做出巨大贡献，而通过适当定制这些行为是完全可以预防的并战略性地采取在临床环境中有效、具有成本效益且可持续的干预措施。 NIDA 已经认识到这一转化差距，并为候选人的研究团队提供了资金，以调整和优化 EBI 方法，以便在戒毒治疗和惩教环境中的重点人群中实施。修订后的 K02（独立科学家奖）中提出的活动为候选人提供了必要的框架和发布时间，以促进针对这一优先人群的下一代艾滋病毒预防和依从性计划，最终目标是改善艾滋病毒的流行。